Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer

Nutrition and Cancer

Volumn 62, Issue 8, 2010, Pages 1036-1043

  DeVere White, Ralph W ^a   Tsodikov, Alexander ^b   Stapp, Eschelle C ^c   Soares, Stephanie E ^a   Fujii, Hajime ^d   Hackman, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d Amino Up Chemical Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; EQUOL; GENISTEIN; ISOFLAVONE; PLACEBO; POLYSACCHARIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; GENISTEIN; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POLYSACCHARIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; SOYBEANS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78249240074     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.492085     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2009. CA Cancer J Clin 59, 225-249, 2009.
2. Amling CL: Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening? Curr Treat Options Oncol 7, 337-345, 2006.
3. Rackley JD, Clark PE, and Hall MC: Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am 33, 237-246, 2006.
4. Sarkar FH and Li Y: Soy isoflavones and cancer prevention. Cancer Invest 21, 744-757, 2003.
5. Yan L and Spitznagel EL: Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 89, 1155-1163, 2009.
6. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, et al.: Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95, 65-71, 2004.
7. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, et al.: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65, 6934-6942, 2005.
8. Handayani R, Rice L, Cui Y, Medrano TA, Samedi VG, et al.: Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr 136, 75-82, 2006.
9. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, et al.: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129, 1628-1635, 1999.
10. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, and Elgavish A: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 135, 989-995, 2005.
11. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, et al.: Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 132, 552S-558S, 2002. (Pubitemid 34208769)
12. Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, and Kurzer MS: Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 137, 1769-1775, 2007.
13. Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, et al.: Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 130, 1695-1699, 2000.
14. Miura T, Yuan L, Sun B, Fujii H, Yoshida M, et al.: Isoflavone aglycone produced by culture of soybean extracts with basidiomycetes and its antiangiogenic activity. Biosci Biotechnol Biochem 66, 2626-2631, 2002.
15. U. S. Department of Agriculture, Agricultural Research Service: USDA-Iowa Sate University database on the isoflavone content of food, Release 1.3, 2002.
16. Yuan L, Wagatsuma C, Sun B, Kim JH, and Surh YJ: The role of betaglucuronidase in induction of apoptosis by genistein combined polysaccharide (GCP) in xenogeneic mice bearing human mammary cancer cells. Ann NY Acad Sci 1010, 347-349, 2003.
17. Bemis DL, Capodice JL, Desai M, Buttyan R, and Katz AE: A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent antiprostate cancer activity in vitro and in vivo. Clin Cancer Res 10, 5282-5292, 2004.
18. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, et al.: GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and-independent mechanisms. Prostate 67, 521-535, 2007.
19. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, et al.: Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res 13, 6204-6216, 2007.
20. Burich RA, Holland WS, Vinall RL, Tepper C, White RW, et al.: Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int 102, 1458-1466, 2008.
21. Ghafar MA, Golliday E, Bingham J, Mansukhani MM, Anastasiadis AG, et al.: Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med 8, 493-497, 2002.
22. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, et al.: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63, 259-263, 2004.
23. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, et al.: Longterm dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 135, 1400-1406, 2005.
24. Barnes S, Coward L, Kirk M, and Sfakianos J: HPLC-mass spectrometry analysis of isoflavones. Proc Soc Exp Biol Med 217, 254-262, 1998.
25. Laird NM and Ware JH: Random-effects models for longitudinal data. Biometrics 38, 963-974, 1982.
26. Taylor JM and Wang Y: Surrogate markers and joint models for longitudinal and survival data. Control Clin Trials 23, 626-634, 2002.
27. Ramirez ML, Nelson EC, De Vere White RW, Lara PN, and Evans CP: Current applications for prostate-specific antigen doubling time. Eur Urol 54, 291-300, 2008.
28. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, et al.: Clinical characteristics and pharmacokinetics of purified soy isoflavones: multipledose administration to men with prostate neoplasia. Nutr Cancer 48, 160-170, 2004.
29. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, et al.: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8, 132, 2008.
30. Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS, and Slaton JW: Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer 60, 7-13, 2008.
31. Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, et al.: A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer 60, 145-154, 2008.
32. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, et al.: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174, 1065-1069, 1069-1070, 2005.
33. Schroder FH, Roobol MJ, Boeve ER, de Mutsert R, Zuijdgeestvan Leeuwen SD, et al.: Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 48, 922-930, 930-931, 2005.
34. Engelhardt PF and Riedl CR: Effects of one-year treatment with isoflavone extract from red clover on prostate, liver function, sexual function, and quality of life in men with elevated PSA levels and negative prostate biopsy findings. Urology 71, 185-190, 2008.
35. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, and Thompson IM: Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 99, 1510-1515, 2007.
36. Johnstone PA, Rossi PJ, Jani AB, and Master V. "Insignificant" prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer Prostatic Dis 10, 237-241, 2007.
37. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al.: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320-1328, 2009.
38. Guy L, Vedrine N, Urpi-Sarda M, Gil-Izquierdo A, Al-Maharik N, et al.: Orally administered isoflavones are present as glucuronides in the human prostate. Nutr Cancer 60, 461-468, 2008.
39. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, et al.: Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77, 875-882, 2003.
40. Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, et al.: Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer 59, 169-175, 2007.
41. Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, et al.: A Phase IIrandomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 59, 163-168, 2007.
42. Wang Y, Raffoul JJ, Che M, Doerge DR, Joiner MC, et al.: Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 166, 73-80, 2006.